Loading…
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. It also provides MyoPro 2 that includes control technology, configuration software and user interface, and pop-out battery for extended use of the brace; MyoPro2+, which comprises 3D printed orthotics capability, software enhancements, and a design for donning and doffing of the device; MyoGames, a virtual training platform; and MyoPro 2x Video Library. In addition, the company offers MyoCare, a post-delivery program that provides follow-up care with clients, therapists, and referral sources; MYOMO; MyoPal; and MyoCoach. Its products are designed to help adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products through various sales channels, including orthotics and prosthetics providers, veteran's administration, and distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Burlington, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $41M | $-13M | $-16M | $-18M | -136.6% | 25.7% | 151.9% |
| 2024 | $33M | $-5M | $-6M | $-5M | -25.0% | 69.2% | -24.1% |
| 2023 | $19M | $-8M | $-8M | $-6M | -90.6% | 23.7% | -24.0% |
| 2022 | $16M | $-10M | $-11M | $-10M | -168.6% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 15.56 | 19.24 | 32.55 | 40.93 |
| Operating Revenue | - | 15.56 | 19.24 | 32.55 | 40.93 |
| Cost Of Revenue | - | 5.30 | 6.06 | 9.37 | 14.04 |
| Gross Profit | - | 10.25 | 13.18 | 23.19 | 26.89 |
| Operating Expense | - | 20.93 | 21.41 | 29.39 | 41.29 |
| Research And Development | - | 2.48 | 2.64 | 4.77 | 6.94 |
| Selling General And Administration | - | 18.44 | 18.78 | 24.62 | 34.35 |
| Total Expenses | - | 26.23 | 27.47 | 38.76 | 55.33 |
| Operating Income | - | -10.67 | -8.23 | -6.21 | -14.40 |
| Total Operating Income As Reported | - | -10.67 | -8.23 | -6.21 | -14.40 |
| EBITDA | - | -10.13 | -7.71 | -5.43 | -12.64 |
| Normalized EBITDA | - | -10.13 | -7.71 | -5.43 | -12.42 |
| EBIT | - | -10.67 | -8.23 | -6.21 | -14.62 |
| Interest Income | 0 | 0.09 | 0.41 | 0.39 | - |
| Interest Expense | 0.02 | - | - | - | 0.45 |
| Net Interest Income | - | 0.09 | 0.41 | 0.39 | -0.45 |
| Other Non Operating Income Expenses | -0.02 | 0 | 0 | - | - |
| Other Income Expense | -0.02 | -0.07 | -0.17 | - | -0.22 |
| Interest Income Non Operating | 0 | 0.09 | 0.41 | 0.39 | - |
| Interest Expense Non Operating | 0.02 | - | - | - | 0.45 |
| Net Non Operating Interest Income Expense | - | 0.09 | 0.41 | 0.39 | -0.45 |
| Pretax Income | - | -10.65 | -7.99 | -5.82 | -15.07 |
| Tax Provision | - | 0.07 | 0.16 | 0.37 | 0.50 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | -0.05 |
| Net Income Continuous Operations | - | -10.72 | -8.15 | -6.18 | -15.57 |
| Net Income From Continuing And Discontinued Operation | - | -10.72 | -8.15 | -6.18 | -15.57 |
| Net Income From Continuing Operation Net Minority Interest | - | -10.72 | -8.15 | -6.18 | -15.57 |
| Net Income | - | -10.72 | -8.15 | -6.18 | -15.57 |
| Net Income Common Stockholders | - | -10.72 | -8.15 | -6.18 | -15.57 |
| Net Income Including Noncontrolling Interests | - | -10.72 | -8.15 | -6.18 | -15.57 |
| Normalized Income | - | -10.72 | -8.15 | -6.18 | -15.40 |
| Diluted NI Availto Com Stockholders | - | -10.72 | -8.15 | -6.18 | -15.57 |
| Basic Average Shares | - | 7.05 | 29.50 | 37.76 | 41.86 |
| Diluted Average Shares | - | 7.05 | 29.50 | 37.76 | 41.86 |
| Reconciled Depreciation | - | 0.54 | 0.52 | 0.78 | 1.98 |
| Reconciled Cost Of Revenue | - | 5.30 | 6.06 | 9.37 | 14.04 |
| Total Unusual Items | 0 | - | - | - | -0.22 |
| Total Unusual Items Excluding Goodwill | 0 | - | - | - | -0.22 |
| Special Income Charges | 0 | - | - | - | - |
| Gain On Sale Of Security | - | - | - | - | -0.22 |
| General And Administrative Expense | - | - | 9.73 | 12.38 | 13.96 |
| Other Gand A | - | - | 9.73 | 12.38 | 13.96 |
| Selling And Marketing Expense | - | - | 9.04 | 12.24 | 20.39 |
| Otherunder Preferred Stock Dividend | 0.64 | 0 | - | - | - |
| Earnings From Equity Interest | 0 | -0.07 | -0.17 | 0 | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Myomo, Inc.this co. | MYO | $50M | -3.20 | 4.37 | -136.6% | -4.36 |
| LENSAR, Inc. | LNSR | $68M | -1.98 | -2.61 | 131.7% | -2.88 |
| DocGo Inc. | DCGO | $56M | -0.31 | 0.39 | -126.7% | -0.47 |
| aTyr Pharma, Inc. | ATYR | $50M | -0.68 | 0.75 | -109.8% | -0.68 |
| Actuate Therapeutics, Inc. Common stock | ACTU | $46M | -2.09 | 5.86 |
| - |
| - |
| - |
| - |
| -280.5% |
| - |
| Accuray Incorporated | ARAY | $43M | -27.33 | 0.54 | -2.0% | 8.03 |
| Gossamer Bio, Inc. | GOSS | $42M | -0.24 | -0.34 | 138.8% | -1.31 |
| Tevogen Bio Holdings Inc. | TVGN | $41M | -1.57 | -2.42 | 154.2% | -1.89 |
| INmune Bio Inc. | INMB | $36M | -0.78 | 1.53 | -195.3% | -0.40 |
| Peer Median | - | -1.18 | 0.46 | -55.9% | -0.68 | |